Halyard Health (NYSE: HYH) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitabiliy and dividends.

Insider & Institutional Ownership

90.3% of Halyard Health shares are owned by institutional investors. Comparatively, 95.2% of DENTSPLY SIRONA shares are owned by institutional investors. 1.3% of Halyard Health shares are owned by company insiders. Comparatively, 2.0% of DENTSPLY SIRONA shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.


This table compares Halyard Health and DENTSPLY SIRONA’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Halyard Health 3.06% 8.29% 4.44%
DENTSPLY SIRONA 9.42% 7.37% 5.21%

Volatility and Risk

Halyard Health has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500.

Valuation & Earnings

This table compares Halyard Health and DENTSPLY SIRONA’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Halyard Health $1.60 billion 1.23 $178.00 million $1.03 40.83
DENTSPLY SIRONA $3.87 billion 3.33 $820.80 million $1.55 36.26

DENTSPLY SIRONA has higher revenue and earnings than Halyard Health. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Halyard Health, indicating that it is currently the more affordable of the two stocks.


DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Halyard Health does not pay a dividend. DENTSPLY SIRONA pays out 22.6% of its earnings in the form of a dividend.

Analyst Ratings

This is a summary of current ratings and recommmendations for Halyard Health and DENTSPLY SIRONA, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halyard Health 0 1 3 0 2.75
DENTSPLY SIRONA 1 2 8 0 2.64

Halyard Health presently has a consensus target price of $41.67, suggesting a potential downside of 0.91%. DENTSPLY SIRONA has a consensus target price of $67.60, suggesting a potential upside of 20.26%. Given DENTSPLY SIRONA’s higher possible upside, analysts clearly believe DENTSPLY SIRONA is more favorable than Halyard Health.


DENTSPLY SIRONA beats Halyard Health on 12 of the 16 factors compared between the two stocks.

Halyard Health Company Profile

Halyard Health, Inc. is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections. The Company address healthcare needs, such as reducing the use of opioids, while helping patients move from surgery to recovery. The Medical Devices segment’s products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes. The S&IP segment includes product offerings, such as sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves.


DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.

Receive News & Stock Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related stocks with our FREE daily email newsletter.